Transgene

Transgene Cash Conversion Cycle

The Cash Conversion Cycle (CCC) of Transgene (TNG.PA) as of Nov 18, 2026 is 71.19. In the previous year, Cash Conversion Cycle (CCC) was 37.20 — a change of 91.37% (higher).

Cash Conversion Cycle

71.19

YoY

91.37%

Last updated:

Cash Conversion Cycle (CCC) of Transgene is 2024 71.19 . Cash Conversion Cycle (CCC) of Transgene was 2023 37.20 . It decreases by 91.37% higher compared to the previous year.

The Transgene Cash Conversion Cycle history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion Cycle
Date
Cash Conversion Cycle
Jan 1, 2017
125.50 EUR
Jan 1, 2018
40.40 EUR
Jan 1, 2019
63.80 EUR
Jan 1, 2020
65.12 EUR
Jan 1, 2021
131.99 EUR
Jan 1, 2022
22.75 EUR
Jan 1, 2023
37.20 EUR
Jan 1, 2024
71.19 EUR
The Transgene Cash Conversion Cycle history
YEARCash Conversion CycleYoY
71.19+91.37%
37.20+63.48%
22.75-82.76%
131.99+102.68%
65.12+2.08%
63.80+57.93%
40.40-67.81%
125.50+25.83%
99.74+46.51%
68.08+34.42%
50.64—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Transgene Stock analysis

What does Transgene do? Transgene SA is a French biotechnology company specializing in the development and production of therapeutics, with a focus on cancer medications. It has a strong patent portfolio in the field of viral vectors, which are used for targeted gene therapy. The company's main areas of operation are clinical trials, research, and production. Transgene has research and production facilities in Strasbourg and Lyon, with over 100 employees. It has established partnerships with pharmaceutical companies, including Takeda Pharmaceuticals, for the development and marketing of therapeutics. Its flagship product, OncoVir-1®, is an immunomodulator that stimulates the immune system to fight tumor cells. Another promising product is TG4010, a therapeutic vaccine for non-small cell lung carcinoma. Transgene is an emerging company with a promising portfolio of cancer therapeutics, leveraging its expertise in viral vectors and collaborating closely with industry partners to expedite the development of marketable products. Transgene is expected to play a significant role in the development of new and innovative cancer treatments. Transgene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Transgene stock

Cash Conversion Cycle (CCC) of Transgene is 71.19 in 2024.

Cash Conversion Cycle (CCC) of Transgene changed from 37.20 to 71.19, representing a 91.37% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Cycle (CCC) Transgene since 2006 – with annual values, charts, and detailed analysis.

The Cash Conversion Cycle measures how long it takes to convert inventory investments into cash from sales. A shorter CCC indicates more efficient working capital management.

CCC = DSO + DIO - DPO

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Cycle (CCC)'s Transgene with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Cycle (CCC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Cycle (CCC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Transgene

All Key Metrics — Transgene